Naslov
Three-week Open Multi-centre Study of Sustained- release Tramadol in Various Pain Conditions

Autori
Ćurković, Božidar ; Bernik, Nataša

Izvornik
Arzneimittel-Forschung (0004-4172) 53 (2003), 7; 503-506

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
analgesic; centrally-acting; CAS 27203-92-5; tramadol; pain conditions; sustained-release; Tramal retard

Sažetak
299 outpatients were included in this open multi-centre 3-week study of the efficacy and safety of sustained-release tramadol (CAS27203- 92-5, Tramal" retard), in various pain conditions. Tramadol was administered 2 x 100 mg daily without prior introduction using an immediate release formula of the drug or titralion of the dose. Of the 299 outpatienls thaI were the subjecl of this study, 177 patients suffered from musculoskeletal pain, 58 from malignant pain and 44 suffered from postoperative pain, all treated by aloIaI of 57 medical doclors of various promes. The remainder of 20 patienls suffered from pain conditions falling out of the aforementioned three calegories. 274 (83 %) of the patients were adminislered a daily dose of 200 mg tramadol. A satisfaclory analgesic effecl was found in 97 % of all 299 patienls. A good or very good quality of analgesia was present in 76.4 % of the patients.Side effecls were noled in 89 (29.8 %) palienls. A significanl increase of the quality of life (responders) was regislered in 49.1 % of all palienls. Conclusion: 200 mg daily dosage of suslained release Iramadol could be a good option for pain conlrol in musculoskeletal and posloperalive pain condilions, especially when non-sleroidal anti-in11ammalory drugs are conlraindicated.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA